

Case-Control Study on Parkinson's Disease Among Mutualité Sociale Agricole Affiliates in Five Départements

<https://neurodegenerationresearch.eu/survey/case-control-study-on-parkinsons-disease-among-mutualite-sociale-agricole-affiliates-in-five-departements-2/>

Title of study

Case-Control Study on Parkinson's Disease Among Mutualité Sociale Agricole Affiliates in Five Départements

Acronym for cohort

TERRE

Name of Principal Investigator - Title

Dr

Name of Principal Investigator - First name

Alexis

Name of Principal Investigator - Last name

Elbaz

Address of institution -Institution

INSERM

Address of institution - Street address

16 Avenue Paul Vaillant Couturier

Address of institution - City

VILLEJUIF

Address of institution - Postcode

94807

Country

France

Website

Contact email

alexis.elbaz@inserm.fr

Funding source

ANR - ANSES - France Parkinson

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Parkinson's disease

Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)

To study the association of professional exposure to pesticides with Parkinson's disease and the role of gene-environment interactions

Q2b. What distinguishes this case-control study from other studies?

Detailed individual data on professional exposure to pesticides in farmers. Population-based study.

Q3a. i) Number of publications that involve use of your cohort to date

15

Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)

Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

1. Chapuis, J., F. Moisan, G. Mellick, A. Elbaz, P. Silburn, F. Pasquier, D. Hannequin, C. Lendon, D. Campion, P. Amouyel and J. C. Lambert (2008). "Association study of the NEDD9 gene with the risk of developing Alzheimer's and Parkinson's disease." Hum Mol. Genet 17(18): 2863-2867. 2. Dutheil, F., P. Beaune, C. Tzourio, M.-A. Lorient and A. Elbaz (2010). "Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson's disease." Arch. Neurol 67(6): 739-745. 3. Elbaz, A., J. Clavel, P. J. Rathouz, F. Moisan, J. P. Galanaud, B. Delemotte, A. Alperovitch and C. Tzourio (2009). "Professional exposure to pesticides and Parkinson's disease." Ann Neurol 66: 494-504.

Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study

Q4a. Study criteria: what is the age range of participants at recruitment? Age in years
From:

18

Q4a. Study criteria: what is the age range of participants at recruitment? To:

Q4b. Study criteria: what are the inclusion criteria?

Case subjects: first LDD requests for Parkinson's disease (18-75 years old). Controls: treatment guarantee requests (random); matched to cases according to age, gender, and département of residence.

Q4c. Study criteria: what are the exclusion criteria?**Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?**

1-1,000

Q5b. What is the expected number of control participants?

501-1,000

Q6a. Please describe what measures are used to characterise participants

Clinical examination

Q6b. Are there additional measures for participants with the clinical disorder?

MMSE

Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

No

If YES please specify

Q7. What is the study design?

Nested case control

Q8. Are your cases matched by

Age|Sex

Q9a. Does your study includes a specialised subset of control participants?

No

Q9b. If your study includes a specialised subset of control participants please describe**Q10a. Is data collection for this study**

Closed to new patients

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

Q11. Are data collected

Only through the study

Q12. Is there a system in place to enable re-contact with patients for future studies?

No

Q13a. Please give information on data stored in a database (1)

Data summarised in database

% Available

Q13a. Please give information on data stored in a database (2)

% Available

Q13a. Please give information on data stored in a database (3)

% Available

Q13a. Please give information on data stored in a database (4)

% Available

Q13a. Please give information on data stored in a database (5)

% Available

Please specify language used

% Available

Q13b. Please give information on how data is held as individual records

% Available

Q14a. Are data available to other groups?

Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?

Access through collaboration with PI only

Q15. What data sharing policy is specified as a condition of use?

No policy exists

Q16a. Are tissues/samples/DNA available to other groups?

No

Q16b i) If yes, please describe below

Q16b. ii) In what form are tissues/samples/DNA supplied?

Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

No

Q17. Is information on biological characteristics available to other groups?

No

Types:

Case Control Studies

Member States:

France

Diseases:

Parkinson's disease & PD-related disorders

Years:

2016

Database Categories:

N/A

Database Tags:

N/A